BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 20213764)

  • 1. Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
    Ali S; Banerjee S; Schaffert JM; El-Rayes BF; Philip PA; Sarkar FH
    J Cell Biochem; 2010 May; 110(1):171-81. PubMed ID: 20213764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.
    Ali S; Banerjee S; Ahmad A; El-Rayes BF; Philip PA; Sarkar FH
    Mol Cancer Ther; 2008 Jun; 7(6):1708-19. PubMed ID: 18566242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy.
    Ali S; El-Rayes BF; Sarkar FH; Philip PA
    Mol Cancer Ther; 2005 Dec; 4(12):1943-51. PubMed ID: 16373709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.
    El-Rayes BF; Ali S; Ali IF; Philip PA; Abbruzzese J; Sarkar FH
    Cancer Res; 2006 Nov; 66(21):10553-9. PubMed ID: 17079479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
    Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
    Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
    Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
    Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells.
    Rahman KM; Ali S; Aboukameel A; Sarkar SH; Wang Z; Philip PA; Sakr WA; Raz A
    Mol Cancer Ther; 2007 Oct; 6(10):2757-65. PubMed ID: 17913854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-κB signaling by 6-shogaol.
    Zhou L; Qi L; Jiang L; Zhou P; Ma J; Xu X; Li P
    AAPS J; 2014 Mar; 16(2):246-57. PubMed ID: 24424498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.
    Wang YW; Wang SJ; Zhou YN; Pan SH; Sun B
    J Cancer Res Clin Oncol; 2012 May; 138(5):785-97. PubMed ID: 22270965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.
    Kirane A; Toombs JE; Ostapoff K; Carbon JG; Zaknoen S; Braunfeld J; Schwarz RE; Burrows FJ; Brekken RA
    Clin Cancer Res; 2012 Sep; 18(18):5031-42. PubMed ID: 22829202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
    Gadgeel SM; Ali S; Philip PA; Wozniak A; Sarkar FH
    Cancer; 2009 May; 115(10):2165-76. PubMed ID: 19288574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
    Iwai T; Moriya Y; Shirane M; Fujimoto-Ouchi K; Mori K
    Oncol Rep; 2012 Apr; 27(4):923-8. PubMed ID: 22209766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
    Lin J; Wu H; Shi H; Pan W; Yu H; Zhu J
    PLoS One; 2013; 8(10):e76169. PubMed ID: 24155892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emodin potentiates the antitumor effects of gemcitabine in pancreatic cancer cells via inhibition of nuclear factor-κB.
    Liu A; Chen H; Tong H; Ye S; Qiu M; Wang Z; Tan W; Liu J; Lin S
    Mol Med Rep; 2011; 4(2):221-7. PubMed ID: 21468555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coix seed emulsion synergistically enhances the antitumor activity of gemcitabine in pancreatic cancer through abrogation of NF-κB signaling.
    Qian Y; Yang B; Xiong Y; Gu M
    Oncol Rep; 2016 Sep; 36(3):1517-25. PubMed ID: 27459907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway.
    Wang Y; Zhou Y; Jia G; Han B; Liu J; Teng Y; Lv J; Song Z; Li Y; Ji L; Pan S; Jiang H; Sun B
    Biochem Pharmacol; 2014 Apr; 88(3):322-33. PubMed ID: 24522113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
    Nagaraj NS; Washington MK; Merchant NB
    Clin Cancer Res; 2011 Feb; 17(3):483-93. PubMed ID: 21266529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
    Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
    Sloss CM; Wang F; Liu R; Xia L; Houston M; Ljungman D; Palladino MA; Cusack JC
    Clin Cancer Res; 2008 Aug; 14(16):5116-23. PubMed ID: 18698029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.